Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note issued to investors on Friday,Benzinga reports. The firm currently has a $9.00 price target on the stock.

A number of other equities analysts also recently commented on LCTX. Maxim Group dropped their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th. D. Boral Capital restated a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $4.80.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $0.60 on Friday. The stock has a market capitalization of $132.41 million, a PE ratio of -5.01 and a beta of 1.18. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its position in shares of Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after acquiring an additional 18,053 shares during the period. Defender Capital LLC. boosted its position in shares of Lineage Cell Therapeutics by 0.6% in the third quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock valued at $4,528,000 after acquiring an additional 29,223 shares during the period. MAI Capital Management boosted its position in shares of Lineage Cell Therapeutics by 2.2% in the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock valued at $1,516,000 after acquiring an additional 35,907 shares during the period. State Street Corp boosted its position in shares of Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after acquiring an additional 45,483 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Lineage Cell Therapeutics by 10.0% in the second quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock valued at $582,000 after acquiring an additional 53,022 shares during the period. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.